Consolidative Radiotherapy for Residual PET-Avid Disease on Day +30 Post CAR T-Cell Therapy in Non-Hodgkin Lymphoma.

O Saifi, S C Lester, W G Rule, W Breen, B J Stish, A Rosenthal,J Munoz, Y Lin,P Johnston,S M Ansell, J Paludo, A Khurana,J Villasboas Bisneto,Y Wang, M Iqbal,M Alhaj Moustafa, H S Murthy,M Kharfan-Dabaja,J L Peterson, B S Hoppe

International journal of radiation oncology, biology, physics（2023）

引用 0|浏览3

暂无评分

摘要

NHL patients who achieve PR by PET to CART are at high risk of local progression. cRT for residual PET-avid disease on day +30 post-CART appears to alter the pattern of relapse and improve LRFS and PFS.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要